Maureen R Benjamins1,2, Peter Lorenz3, Nazia S Saiyed4, Abigail Silva5, Holly J Mattix-Kramer6, Paulina Pys3, Andrew Schulz3. 1. Sinai Urban Health Institute, Chicago, IL, USA. maureen.benjamins@sinai.org. 2. Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA. maureen.benjamins@sinai.org. 3. Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA. 4. Sinai Urban Health Institute, Chicago, IL, USA. 5. Loyola University Parkinson School of Health Sciences and Public Health, Maywood, IL, USA. 6. Loyola University Stritch School of Medicine, Maywood, IL, USA.
Abstract
OBJECTIVES: To examine city-level kidney disease mortality rates and Black:White racial inequities for the USA and its largest cities, and to determine if these measures changed over the past decade. METHODS: We used National Vital Statistics System mortality data and American Community Survey population estimates to calculate age-standardized kidney disease mortality rates for the non-Hispanic Black (Black), non-Hispanic White (White), and total populations for the USA and the 30 most populous US cities. We examined two time points, 2008-2013 (T1) and 2014-2018 (T2), and assessed changes in rates and inequities over time. Racial inequities were measured with Black:White mortality rate ratios and rate differences. RESULTS: Kidney disease mortality rates varied from 2.5 (per 100,000) in San Diego to 24.6 in Houston at T2. The Black kidney disease mortality rate was higher than the White rate in the USA and all cities studied at both time points. In T2, the Black mortality rate ranged from 7.9 in New York to 45.4 in Charlotte, while the White mortality rate ranged from 2.0 in San Diego to 18.6 in Indianapolis. At T2, the Black:White rate ratio ranged from 1.79 (95% CI 1.62-1.99) in Philadelphia to 5.25 (95% CI 3.40-8.10) in Washington, DC, compared to the US rate ratio of 2.28 (95% CI 2.25-2.30). Between T1 and T2, only one city (Nashville) saw a significant decrease in the Black:White mortality gap. CONCLUSIONS: The largest US cities experience widely varying kidney disease mortality rates and widespread racial inequities. These local data on racial inequities in kidney disease mortality can be used by city leaders and health stakeholders to increase awareness, guide the allocation of limited resources, monitor trends over time, and support targeted population health strategies.
OBJECTIVES: To examine city-level kidney disease mortality rates and Black:White racial inequities for the USA and its largest cities, and to determine if these measures changed over the past decade. METHODS: We used National Vital Statistics System mortality data and American Community Survey population estimates to calculate age-standardized kidney disease mortality rates for the non-Hispanic Black (Black), non-Hispanic White (White), and total populations for the USA and the 30 most populous US cities. We examined two time points, 2008-2013 (T1) and 2014-2018 (T2), and assessed changes in rates and inequities over time. Racial inequities were measured with Black:White mortality rate ratios and rate differences. RESULTS: Kidney disease mortality rates varied from 2.5 (per 100,000) in San Diego to 24.6 in Houston at T2. The Black kidney disease mortality rate was higher than the White rate in the USA and all cities studied at both time points. In T2, the Black mortality rate ranged from 7.9 in New York to 45.4 in Charlotte, while the White mortality rate ranged from 2.0 in San Diego to 18.6 in Indianapolis. At T2, the Black:White rate ratio ranged from 1.79 (95% CI 1.62-1.99) in Philadelphia to 5.25 (95% CI 3.40-8.10) in Washington, DC, compared to the US rate ratio of 2.28 (95% CI 2.25-2.30). Between T1 and T2, only one city (Nashville) saw a significant decrease in the Black:White mortality gap. CONCLUSIONS: The largest US cities experience widely varying kidney disease mortality rates and widespread racial inequities. These local data on racial inequities in kidney disease mortality can be used by city leaders and health stakeholders to increase awareness, guide the allocation of limited resources, monitor trends over time, and support targeted population health strategies.
Authors: Dominique Sighoko; Anne Marie Murphy; Bethliz Irizarry; Garth Rauscher; Carol Ferrans; David Ansell Journal: Cancer Causes Control Date: 2017-03-08 Impact factor: 2.506
Authors: Anton C Schoolwerth; Michael M Engelgau; Thomas H Hostetter; Kathy H Rufo; Dolph Chianchiano; William M McClellan; David G Warnock; Frank Vinicor Journal: Prev Chronic Dis Date: 2006-03-15 Impact factor: 2.830
Authors: Ben R Spoer; Justin M Feldman; Miriam L Gofine; Shoshanna E Levine; Allegra R Wilson; Samantha B Breslin; Lorna E Thorpe; Marc N Gourevitch Journal: Prev Chronic Dis Date: 2020-11-05 Impact factor: 2.830